LAVA Therapeutics
LVTX
LVTX was delisted on the 20th of November, 2025.
24 hedge funds and large institutions have $139M invested in LAVA Therapeutics in 2021 Q1 according to their latest regulatory filings, with 24 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
36.38% more ownership
Funds ownership: 0% → 36.38% (+36%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$45.7M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$38.8M |
| 3 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
+$11.2M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$5.24M |
| 5 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$3.64M |
Top Sellers
LVTX Hedge Fund Activity: Q1 2021 in Review
24 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in LAVA Therapeutics (LVTX) for Q1 2021, worth a combined $139M.
Buyers outnumbered sellers: 24 funds opened new LVTX positions and 0 closed out — a net gain of 24 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Novo Holdings A/S, opening a new position worth an estimated $45.7M.
- 24 institutional investors held LAVA Therapeutics (LVTX) as of Q1 2021, up from 0 in Q4 2020.
- Funds reported $139M of LAVA Therapeutics stock for Q1 2021.
- 24 funds opened new LAVA Therapeutics positions in Q1 2021 and 0 closed out, a net change of +24 holders.
- The largest LAVA Therapeutics buyer in Q1 2021 was Novo Holdings A/S, an estimated $45.7M added.
Based on aggregated 13F filings for Q1 2021.